R&D channel feed

No­var­tis-led group de­vel­ops new class of an­tipar­a­sitic drug tar­get­ing dis­eases caused by try­panosomes

Last year
Discovery

Gen­fit, Ipsen tout piv­otal tri­al read­out for rare liv­er dis­ease, head to­ward FDA and EMA sub­mis­sions

Last year

Can­cer biotech In­ten­si­ty Ther­a­peu­tics looks to pull in $16M+ IPO

Last year
Financing

Madri­gal seeks ac­cel­er­at­ed ap­proval for ex­per­i­men­tal NASH treat­ment a week af­ter In­ter­cept re­jec­tion

Last year
FDA+

Cyteir to dis­solve as on­col­o­gy biotech scraps its fi­nal clin­i­cal at­tempt two years af­ter IPO

Last year
People

PTC Ther­a­peu­tics re­ports sec­ond tri­al flop for late-stage pro­gram

Last year

Liq­uidia and Unit­ed Ther­a­peu­tics could bring new lung in­di­ca­tion in­to le­gal saga

Last year

As it search­es for a new CEO, Il­lu­mi­na faces a high-stakes year of chal­lenges

Last year
People

BioX­cel stock craters af­ter dis­clo­sure of in­ves­ti­ga­tor's fal­si­fied safe­ty re­port in Alzheimer's study

Last year

Eiger Bio­Phar­ma­ceu­ti­cals to fo­cus on GLP-1 can­di­date, cut work­force by 25%

Last year
People

Aldeyra eyes po­ten­tial­ly piv­otal tri­al in re­tini­tis pig­men­tosa af­ter small open-la­bel read­out

Last year

Sanofi hints at 'class ef­fec­t' for mR­NA flu shot as it un­veils vac­cine R&D plans dri­ven by $3.2B deal

Last year
Pharma

In a first, FDA signs off on Cell­Tran­s' type 1 di­a­betes cell ther­a­py days af­ter in­dus­try's eyes fix­at­ed on Ver­tex da­ta

Last year
Cell/Gene Tx
FDA+

FDA ad­comm votes in fa­vor of Ipsen's fi­brodys­pla­sia drug

Last year
Pharma

Q&A with Tran­sCel­er­ate’s new CEO Jan­ice Chang: Bring­ing the tri­al in­fra­struc­ture to pa­tients

Last year
FDA+

A cen­tu­ry af­ter the last ma­jor TB vac­cine break­through, Gates and Well­come com­mit $550M for PhI­II test of GSK shot

Last year

Meet ‘Fan­zor,’ a cousin of CRISPR and Feng Zhang’s new gene edit­ing tool

Last year
Discovery

With just one re­sponse in 47 pa­tients, Foghorn stops work on lead can­di­date in ad­vanced eye can­cer

Last year

Eton hand­ed sec­ond CRL for methanol poi­son­ing treat­ment

Last year
FDA+

Fresh off ap­proval, Ab­b­Vie and Gen­mab's CD3xCD20 bis­pe­cif­ic Ep­kin­ly scores in an­oth­er type of blood can­cer

Last year

Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Last year
Cell/Gene Tx

Al­most 40 years af­ter an ad­com­m's warn­ing: FDA and spon­sors with­draw ap­proval for an­a­bol­ic steroid

Last year

Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

Last year
Cell/Gene Tx

Af­ter cut­ting back on Vuity last fall, Ab­b­Vie culls a sec­ond-gen pres­by­opia eye drop

Last year
Pharma
First page Previous page 77787980818283 Next page Last page
A service from the Financial Times